The clinical use of staging bone scan in patients with breast carcinoma
Open Access
Abstract
BACKGROUND: Using the new 2003 American Joint Committee on Cancer (AJCC) staging system, the authors evaluated the usefulness of the staging bone scan in patients with primary breast carcinoma.METHODS: The authors examined 1939 patients with primary breast carcinoma for staging bone scan who were treated at a single institution. Pathologic stage was assigned retrospectively according to the 1988 and the 2003 AJCC staging systems.RESULTS: Bone metastasis rates were 0.7% (4 of 586) for patients with Stage I disease, 0.7% (5 of 699) for patients with Stage IIA disease, 2.1% (10 of 479) for patients with Stage IIB disease, 4.5% (7 of 154) for patients with Stage IIIA disease, and 10.5% (2 of 19) for patients with Stage IIIB disease according to the 1988 AJCC staging system. The authors found a significant difference in the bone metastasis rate between patients with Stages IIA and IIB disease in the 1988 staging system (P = 0.039). Reevaluating the patients by the 2003 system resulted in significant upstaging, especially for patients with Stage II/III disease. According to the 2003 staging system, bone metastasis rates were 0.7% (4 of 586) for patients with Stage I disease, 0.6% (4 of 648) for patients with Stage IIA disease, 0.6% (2 of 310) for patients with Stage IIB disease, 4.0% (9 of 225) for patients with Stage IIIA disease, 16.7% (2 of 12) for patients with Stage IIIB disease, and 4.4% (7 of 158) for patients with Stage IIIC disease. It was noteworthy that there was a significant difference between Stages IIB and IIIA in the 2003 staging system (P = 0.010).CONCLUSIONS: Stage reclassification using the new AJCC staging system resulted in upstaging of high‐risk patients, as well as a significant decrease in the bone metastasis rate in patients with Stage IIB breast carcinoma. Considering the cost‐effectiveness of staging bone scan, the data suggested that it was of little value for patients with Stage I and II breast carcinoma, but was highly recommended for patients with worse than Stage III disease by the new 2003 staging system. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- Current role of bone scan with phosphonates in the follow-up of breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Screening for “Cancer”: When is it Valid?—Lessons from the Mammography ExperienceRadiology, 2003
- Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific SurvivalJournal of Clinical Oncology, 2003
- Frequency and distribution pattern of distant metastases in breast cancer patients at the time of primary presentationArchives of Gynecology and Obstetrics, 2002
- Revision of the American Joint Committee on Cancer Staging System for Breast CancerJournal of Clinical Oncology, 2002
- Staging of Breast Cancer: New Recommended Standard ProcedureBreast Cancer Research and Treatment, 2002
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- What Do Breast Cancer Patients Benefit from Staging Bone Scintigraphy?Japanese Journal of Clinical Oncology, 2001
- Staging Investigations in Patients With Breast CancerArchives of Surgery, 1999
- Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-upJAMA, 1994